Photo: Depositphotos
May 25, 2025, 08:11
Manas Dubey: SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) Clinical Trials
Manas Dubey, Medical Oncologist and Hemat-Oncologist at Kamla Nehru Memorial Hospital, posted on X:
“SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial), two landmark clinical trials.
Results:
12-year DFS rates –
Tamoxifen alone (67.0%), Tamoxifen + Ovarian Function Suppression (OFS) (70.5%), and Exemestane + OFS (73.5%).”
More posts featuring Breast Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38